Select Page

Home » ARC Fertility Supports Preimplantation Genetic Diagnosis (PGD) for Healthier Babies

ARC Fertility Supports Preimplantation Genetic Diagnosis (PGD) for Healthier Babies

by | Feb 18, 2015 | News, Press Releases

Saratoga, CA (February 18, 2015) – As reproductive science advances, fertility scientists, embryologists and doctors are constantly developing new techniques to help families have healthy pregnancies and healthy children. One such advancement, preimplantation genetic diagnosis (PGD), is an important addition to successful fertility treatments, and is being supported by ARC Fertility, the largest network of fertility specialists in the county. PGD involves testing a day 5 embryo (blastocyst) for a specific known genetic abnormality, and preimplantation genetic screening (PGS) is screening of a blastocyst to determine if the chromosomes are normal. According to a recently published report, the global preimplantation genetic diagnosis market is estimated to reach $47.4 million by the end of 2018.

Dr. David Adamson, founder and CEO of ARC, says, “PGD has contributed to the reduction of debilitating genetic disorders such as cystic fibrosis, Huntington’s Disease, muscular dystrophy, and many others. PGS is a new technology that is being used to select the healthiest embryos prior to implantation. It has been shown to reduce the risk of miscarriage and results in higher implantation rates. Its optimal role in managing IVF patients is still being evaluated. Both PGD and PGS, when used appropriately in selected patients, can play an important role in healthy pregnancies and healthy children.”

PGD is used to prevent specific diseases, often in couples who are not infertile but carry a risk of passing on genetic disorders, while PGS is generally used in infertile patients or those with recurrent pregnancy loss to identify the most normal appearing blastocysts for transfer back into the uterus. Uses for PGS are still being evaluated in clinical trials to identify their optimal application in infertile patients.

“PGD and PGS are technologies that can only be performed because IVF, which creates embryos in the laboratory, was developed” adds Adamson. “Screening gives us the ability to test those embryos before implantation and avoid implanting an embryo that has an abnormality. It allows us to give our patients peace of mind in an already stressful and complicated situation.”

About Advanced Reproductive Care, Inc. (ARC)

With more than 17 years of experience, Advanced Reproductive Care, Inc. (ARC) provides affordable, evidence-based fertility treatment packages and financing options to people living with infertility. Founded by world-renowned, Stanford-trained, board certified reproductive endocrinologist Dr. David Adamson, ARC offers the largest network of board-certified fertility specialists in the United States. To check out our exciting new and improved website, please visit www.arcfertility.com

 

Skip to content